Alpha-dystroglycan is a cell-surface glycoprotein that acts as a receptor for both extracellular matrix proteins containing laminin-G domains and certain arenaviruses. Receptor binding is thought to be mediated by a post-translational modification, and defective binding with laminin underlies a subclass of congenital muscular dystrophy. Here, using mass spectrometry-and NMR-based structural analyses, we identified a phosphorylated O-mannosyl glycan on the mucin-like domain of recombinant alpha-dystroglycan, which was required for laminin binding. We demonstrated that patients with muscle-eye-brain disease and Fukuyama congenital muscular dystrophy, as well as mice with myodystrophy, commonly have defects in a post-phosphoryl modification of this phosphorylated O-linked mannose, and that this modification is mediated by the likeacetylglucosaminyltransferase (LARGE) protein. Our findings expand our understanding of the mechanisms that underlie congenital muscular dystrophy.
DG subunit and a transmembrane β-DG subunit (1) . α-DG serves as a receptor for extracellular matrix laminin G domain-containing ligands such as laminin (1) and agrin (2) in both muscle and brain, and these interactions depend on an unidentified post-translational α-DG modification. α-DG is also the cellular receptor for lymphocytic choriomeningitis virus (LCMV), Lassa fever virus (LFV), and clade C New World arenaviruses (3, 4) . Although the binding sites for LCMV and LFV on α-DG have not yet been identified, they are thought to overlap with the modification recognized by laminin (5, 6) .
Glycosyltransferase-mediated glycosylation is one form of post-translational modification that can modulate protein structure and function. The main forms in mammals are N-and Oglycosylation, and these are distinguished by how the oligosaccharide moiety links to the amino acid. Mutations in six known or putative glycosyltransferase genes-POMT1 (7) , POMT2 (8), POMGnT1 (9) , fukutin (10) , FKRP (11) , and LARGE (12)-have been identified in patients with congenital muscular dystrophy (CMD). These disorders cover a spectrum of abnormalities affecting the brain, eye, and skeletal muscle, and show a dramatic gradient of phenotypic severity ranging from the most devastating in Walker-Warburg syndrome (WWS; OMIM# 236670), to less severe in muscle-eye-brain disease (MEB; OMIM# 253280) and Fukuyama CMD (FCMD; OMIM# 253800), and to mild limb-girdle muscular dystrophies. In these diseases, the ability of α-DG to bind laminin is markedly reduced (13) , suggesting that these (putative) glycosyltransferases participate in the post-translational modification that enables α-DG to bind laminin. Whereas the molecular functions of LARGE, fukutin, and FKRP remain unclear, POMT1/2 (14) and POMGnT1 (9) are known to catalyze two steps in the biosynthesis of an O-mannosyl tetrasaccharide (NeuNAc-α-2,3-Gal-β-1,4-GlcNAc-β-1,2-Man) that is found in high abundance on both brain and muscle α-DG (15, 16) . However, this glycan itself is not likely the laminin-binding moiety, since glycosidase-mediated removal of all or most of the three sugars at the non-reducing terminus does not reduce α-DG binding to laminin (17) .
To determine which post-translational modification is necessary for the α-DG/laminin interaction, we processed wheat germ agglutinin-enriched proteins (glycoproteins) from C57BL/6J (wild type, Wt) muscle using various enzymatic and chemical treatments. We then analyzed the products by immunoblotting with antibodies against α-DG core protein (CORE), the laminin-binding form of α-DG (IIH6), and β-DG core protein (AP83), as well as by laminin overlay assay. Treatment with cold aqueous hydrofluoric acid (HFaq), which specifically cleaves phosphoester linkages (18) resulted in reduction of the α-DG M r from 150-to 70-kDa, loss of IIH6 immunoreactivity and laminin binding ( Fig. 1A) , and loss of binding to LFV and LCMV ( Fig. 1B ). As the M r of N-glycosylated β-DG did not change ( Fig. 1A) , these effects were not caused by the degradation of either peptide or glycosyl linkages. A quantitative solidphase assay revealed that a 97% reduction in total high-affinity binding to laminin was achieved ( Fig. 1C ). HFaq treatment also abolished laminin-receptor activity of α-DG in heart, brain and kidney (fig. S1A). We next tested whether N-glycan and/or the two O-glycans known to modify the laminin-binding form of α-DG-Core1 O-glycan and the O-mannosyl tetrasaccharide (in either the sialylated or fucosylated form) (15, 16) -are sensitive to HFaq treatment. Immunoblotting of Wt-muscle glycoproteins treated with several cocktails of glycosidases that degrade these three glycans showed that the glycosidase-mediated reduction in α-DG glycosylation was impervious to HFaq treatment ( Fig. 1D ). Similar experiment using muscle glycoproteins from the CMD-model mouse LARGE myd , in which a mutation in LARGE prevents the α-DG modification necessary for laminin-binding (19) , revealed that HFaq treatment did not significantly reduce the M r of α-DG ( Fig. 1D ). Thus, HFaq degrades specifically the laminin-binding moiety on α-DG. Finally, we tested the type of phosphorylation involved by digesting Wt-muscle glycoproteins with alkaline phosphatase. The laminin-receptor activity of α-DG (fig. S1B) was not affected, suggesting that functional modification of α-DG involves an internal phosphoryl linkage rather than a monoester-linked phosphate.
To verify that α-DG is phosphorylated, we labeled human embryonic kidney cells (HEK293) expressing Fc-tagged α-DG recombinants ( Fig. 2A ) that are secreted into the medium with [ 32 P]-orthophosphate. Phosphor-imaging showed that secreted DGFc4, which contains only the mucin-like region of α-DG owing to cleavage of its N-terminus by a furin-like protease (20) , was phosphorylated ( Fig. 2B ). When [ 32 P]-DGFc4 was hydrolyzed under conditions conducive to the dissolution of polypeptide and phosphoester linkages to carbohydrates, but not to linkages to amino acids (21), inorganic phosphate but not phospho-amino acids were generated ( fig. S2 ), suggesting that phosphorylation does not occur directly on the peptide. To test if the phosphorylation depends on glycosylation, we expressed DGFc5 in [ 32 P]orthophosphate-labeled human cells derived from POMT1-mutated WWS, POMGnT1mutated MEB, fukutin-mutated FCMD, and control cells, as well as in fibroblasts from Large myd and Wt mice ( Fig. 2C ). All except the POMT1-mutated WWS cells secreted [ 32 P]phosphorylated DGFc5 into the medium, strongly suggesting that phosphorylation occurs on the O-linked mannose of α-DG. By measuring inorganic phosphate following acid hydrolysis, we confirmed that native α-DG purified from rabbit skeletal muscle is phosphorylated, and further quantitated this modification at 4.7 mol phosphate per mol protein (SEM=0.22, n=3).
To assess if CMD cells that synthesize phosphorylated α-DG can further modify the phosphate residue, we immunoprecipitated glycoproteins from mouse Large myd and Wt muscle, as well as from human POMGnT1-mutated MEB, fukutin-mutated FCMD, and control muscle, using immobilized metal affinity chromatography (IMAC)-beads that bind to monoester-linked, but not diester-linked, phosphorylated compounds. Only fukutin-mutated FCMD and Large myd muscle α-DG were captured by the beads, revealing that the phosphate residue does not undergo further modification in these CMD cells (Fig. 2D ). This suggests that fukutin and LARGE participate in a common pathway to assemble the laminin-binding moiety onto the phosphorylated O-linked mannose. This speculation is compatible with the fact that α-DG prepared from Large myd muscle rescued by adenovirus-mediated expression of LARGE regains laminin-receptor activity and concomitantly loses its affinity for IMAC beads ( fig. S3 ). In the case of POMGnT1-mutated MEB patient muscle, several forms of α-DG were observed; the majority of these were captured by the beads, although a certain amount of α-DG with laminin-binding activity was detected in the void fraction (Fig. 2D ). This finding suggests that a defect in POMGnT1 partially inhibits modification on the phosphoryl branch chain of the Omannosyl glycan on α-DG.
DGFc4 produced by HEK293 cells bound to IMAC-beads ( fig. S4A ) and gained lamininbinding activity when it was co-expressed with LARGE ( fig. S4B ); such a gain in activity has also been observed in FCMD, MEB, and Large myd cells, both in this study and elsewhere (22) . To determine the structure of the phosphorylated O-mannosyl glycan that appears to be necessary to assemble the laminin-binding moiety, we prepared O-glycans from HEK293expressed DGFc4 by reductive β-elimination, and isolated the phosphorylated O-glycan using IMAC-beads. LTQ mass spectrometry-based analyses detected prominent ions at m/z 667 ([M-H] − ) and m/z 333 ([M-2H] 2− ) which are assigned as a phosphorylated trisaccharide composed of HexNAc 2 Hexitol 1 (fig. S5 ), and analysis by high performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) revealed the compositional sugars to be GlcNAc, GalNAc, and mannitol ( fig. S6 ). Homo-and heteronuclear NMR techniques were used to assign the 13 C/ 1 H HMQC spectrum of the reduced Oglycan (Fig. 3A) . The GlcNAc (subunit B) was assigned using DQF-COSY and TOCSY spectra with a series of mixing times (fig. S7 ). The GalNAc (subunit C) was partially assigned based on a selective-TOCSY-HSQC spectrum (Fig. 3B ). The GalNAc (subunit C) is linked via a β1-3 linkage to the C3 position on GlcNAc (subunit B), which is in turn connected via a β1-4 linkage to the C4 position on mannitol (subunit A), as evidenced by the observed HMBC cross peaks CH1/BC3 and BH1/AC4 (Fig. 3C) . The phosphate group is attached to the C6 position of the mannitol (subunit A) as determined from the cross peaks 31 P/AH6' and 31 P/ A6H" detected in the 31 P/ 1 H COSY spectrum (Fig. 3D ). The complete NMR resonance assignments of the reduced O-glycan and its inter-residue correlations detected in the NOESY and HMBC spectra are summarized in table S1, and the determined structure is shown in Fig.  3E . To verify that this phosphorylated trisaccharide modifies the mucin-like domain of DGFc4, we enriched the trypsinized peptides using Wisteria Floribunda agglutinin-lectin and analyzed the GalNAc-terminated peptides by LCMS/MS. MS/MS fragmentation patterns at m/z 1318.63 (Fig. 4A), 1420.17 (fig. S9), and 1501.19 (fig. S10 ) identified a peptide (amino acids 374 to 389 of α-DG; Accession ID: CAA45732) bearing these modifications-the phosphorylated trisaccharide in conjunction with Hex-HexNAc-Hex, HexNAc-Hex or Hex. The presence of non-phosphorylated mannose-initiated structures on y3, y4, and y10 ions revealed that Thr 379 is modified by the phosphorylated trisaccharide in all cases (Figs. 4AB, S9 , and S10).
To assess where within the cell α-DG is phosphorylated, we separated the ER and Golgi of DGFc4-overexpressing HEK293 cells using an iodixanol gradient ( fig. S11A ). Immunoprecipitation with IMAC-beads showed that only the Golgi fraction contained phosphorylated DGFc4, suggesting that phosphorylation occurs in the Golgi (fig. S11B ). Mannose-6-phosphorylation is known to occur on N-glycans during their passage through the Golgi, and to serve as the marker for targeting newly synthesized lysosomal enzymes to the lysosome (23) . In this mannose-6-phosphate synthetic pathway, mannose is phosphorylated by the sequential actions of two enzymes: UDP-GlcNAc:lysosomal enzyme GlcNAc-1phosphotransferase (OMIM# 607840), which transfers GlcNAc-1-phosphate to the C6 hydroxyl of mannose; and GlcNAc-1-phosphodiester α-N-acetylglucosaminidase (OMIM# 607985), which removes the terminal GlcNAc to form mannose-6-phosphate. Analysis of fibroblasts derived from patients with Mucolipidosis II (OMIM 252500), which have a defect in GlcNAc-1-phosphotransferase, revealed that they can synthesize the laminin-binding form of α-DG (Fig. 4C) . Thus, an unidentified pathway phosphorylates the C6 hydroxyl of the Omannosyl glycan.
We have identified a phosphorylated O-glycan on recombinant α-DG synthesized in HEK293 cells. Further, our comparative studies of α-DG in CMD and control muscle reveal that the phosphoryl chain on O-mannosyl glycan is required to assemble the laminin-binding moiety, and that LARGE directly participates in the post-phosphorylation biosynthetic pathway. MEB, FCMD and Large myd cells, which have genetically distinct abnormalities, nevertheless show a similar defect in processing of the phosphoryl branch chain on the O-mannosyl glycan (Fig.  4D ). These convergent mechanisms to pathology offer an explanation for previous reports that forced expression of LARGE can circumvent defects in α-DG modification in these CMD cells (22) . We have shown that overexpressing LARGE, a putative glycosyltransferase with catalytic domains sharing homology with β-1,3-N-acetylglucosaminyltransferase and bacterial glycosyltransferase (19) , increases the affinity of the cell surface for both the IIH6 antibody ( Fig.S12A ) and the Vicia villosa lectin (Fig. S12B) . Thus, LARGE is likely to transfer glycosyl moiety to an O-linked mannose-6-phosphate.
To our knowledge, we provide the first evidence that a vertebrate non-GPI-anchored glycoprotein is modified by a phosphodiester linkage. Glycoproteins in the cell walls of yeasts and fungi bear phosphodiester-linked glycans generated by a process involving phosphorylation on the C6 hydroxyl of mannose (24) . It is notable that α-DG, which is well conserved as an epithelial cell-surface protein in species ranging from lower vertebrates to mammals, is likewise modified by this ancient type of glycosylation. A recent study has shown that the most severe form of CMD-WWS-is a genetically heterogeneous disease. Moreover, only 40% of WWS cases are explained by mutations in known CMD-causative genes (24) . Thus, a defect in the phosphorylation of an O-linked mannose may be responsible for severe CMD-in which case the discovery of mutations in novel genes responsible for WWS may not be far off. 
